Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer

Anticancer Research

Volumn 23, Issue 1 B, 2003, Pages 737-744

  Christodoulou, C ^a,b   Klouvas, G ^a   Pateli, A ^a   Mellou, S ^a   Sgouros, J ^a   Skarlos, D V ^a  

^a Henry Dynan Hospital   (Greece)

^b Errikos Dunant Hospital   (Greece)

Author keywords

Breast cancer; Prolonged administration; Trastuzumab; Weekly paclitaxel

Indexed keywords

AROMATASE INHIBITOR; CAPECITABINE; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIMETINDENE; DOCETAXEL; ENALAPRIL; GEMCITABINE; NAVELBINE; ONDANSETRON; PACLITAXEL; PARACETAMOL; TAMOXIFEN; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DERMATITIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HERPES ZOSTER; HOARSENESS; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LONG TERM CARE; MUCOSA INFLAMMATION; NAIL INFECTION; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ONCOGENE NEU; ONYCHOLYSIS; PRIORITY JOURNAL; PRURITUS; PYELONEPHRITIS; RASH; RHINITIS; STOMATITIS; VEIN THROMBOSIS; VERTIGO;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; RECEPTOR, ERBB-2;

EID: 0037231194     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Hortobagyi GN and Khayat D: Targeting progress: The development of growth factor receptor-directed therapy. Semin Oncol 27 (Suppl 9): 2000.
2. Coussens L, Yang-Feng TL, Kiao YC et al.: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-39, 1985.
3. King CR, Kraus MH and Aaronson SA: Amplification of a novel c-erb-B-2 related gene in human mammary carcinoma. Science 229: 974-76, 1985.
4. Akiyama T, Subo C, Ogawara H, Toyoshima K and Yamamoto T: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232: 1644-46, 1986.
5. Slamon DJ, Clark G, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-82, 1987.
6. Slamon DJ, Godolphin W, Jones LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-12, 1989.
7. Hudziak RM, Schlessinger J and Ullrich A: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84: 7159-63, 1987.
8. Seshadri R, Figaira FA, Horsfall JD et al.: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11: 1936-42, 1993.
9. Press MF, Pike MC, Chazin VR et al.: HER-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53: 4960-70, 1993.
10. Pardin PM and Chamness GC: The c-erb-2 proto-ongogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review. Gene 159: 19-27, 1995.
11. Fendly BM, Winget M, Hudziak RM et al.: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER-2/neu gene product. Cancer Res 50: 1550-58, 1990.
12. Hudriak RM, Lewis GD, Winget M et al.: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol: 1165-72, 1989.
13. HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-9, 1992.
14. Pegram M and Slamon D: Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Sem Oncol 27(5) Suppl 9: 13-19, 2000.
15. Pietras RJ, Pegram MD, Finn RS et al: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER2 receptor and DNA-reactive drugs. Oncogene 17: 2235-49, 1998.
16. Pietras RJ, Fendley BM, Chazin VR et al.: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9: 1829-38, 1994.
17. Tokuda Y, Watanabe T, Omuro Y et al.: Dose escalation and pharmacokinetic study at a humanized anti-HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. Br J Cancer 81(8): 1419-25, 1999.
18. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC and Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737-44, 1996.
19. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA and Slamon DJ: Phase II study of receptor-enhanced chemosensitivity, using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-71, 1998.
20. Cobleigh MA, Vogel CL, Tripathy D et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-48, 1999.
21. Slamon DJ, Leyland-Jones B, Shak, Fuchs H et al.: Concurrent administration of anti-HER-2 monoclonal antibody and first line chemotherapy for HER2-overexpressing metastatic breast cancer. N Engl J Med 11: 783-92, 2001.
22. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Fritsche HA, Sneige N, Smith TL and Hortobagyi GN: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2 overexpressing metastatic breast cancer. J Clin Oncol 20: 2002.
23. Burstein HJ, Kuter I, Campos SM et al.: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722-30, 2001.
24. Gianni L, Albanell J, Eiermann W, Bianchi G, Borquez D, Vigano L, Molina R and Baselga J: Feasibility, pharmacology and antitumor activity of Herceptin(r) (H) with doxorubicin and Taxol(r) followed by weekly Taxol(r) (AT&T) in women with HER2-positive advanced breast cancer (ABC). Proc Am Soc Clin Oncol 20: 44a (abstract 134), 2001.
25. Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, Christodoulou Ch et al.: Weekly paclitaxel as first line chemotherapy and trastuzumab in patients with advanced breast cancer. Ann Oncol 12: 1545-51, 2002.
26. Seidman AD, Fornier MN, Esteva FS et al.: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-95, 2001.
27. Perez EA: Paclitaxel in breast cancer. Oncologist 3: 373-89, 1998.
28. Seidman AD, Hudis CA, Albanel J et al.: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353-61, 1998.
29. Pegram M, Hsu S, Lewis G et al.: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapentic agents used for treatment of human breast cancers. Oncogene 18: 2241-51, 1999.
30. Tripathy D, Slamon D, Leyland-Jones B et al.: Treatment beyond progression in the Herceptin pivotal combination chemotherapy trial. Breast Cancer Res Treat 64: 32 (abstract 25), 2000.
31. Reference Criteria Committee of the NYHA. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 7th ed. Boston: Little Brown, 1973.
32. Machin D, Campbell M, Fayers P and Pinol A: Sample size tables for clinical studies, Confidence Intervals, Blackwell Science, 1997.
33. Kaplan E and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-81, 1958.
34. Eidtmann H, Clemens M, von Minckwitz G, Nitz U, Marme A, Niederle N, du Bois A and Habicht A: Trastuzumab (Herceptin(tm)) monotherapy in patients with pretreated metastatic breast cancer. Breast Cancer Res Treat 69: 303 (abstract 528), 2001.
35. Cook-Bruns N: Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61 (Suppl 2): 58-66, 2001.
36. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart JC and Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-26, 2002.
37. Baselga J: Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 61 (Suppl 2): 14-21, 2001.
38. Mass RD, Press M and Anderson S: Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridisation (FISH). Proc Am Soc Clin Oncol 20: 22a, 2001.
39. Perez EA, Vogel CL, Irwin DH, Kirshner JJ and Patel R: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19: 4216-23; 22; for a review, see Perez 1998.
40. Bell R: Duration of therapy in metastatic breast cancer: management using Herceptin(r) Anticancer Drugs 12: 561-8, 2001.
41. Correia O, Azeredo C, Pinto Ferreira E et al.: Nail changes secondary to docetaxel (Taxotere). Dermatology 198(3): 288-90, 1999.
42. Lueftner D, Flath B, Acrivakis C et al.: Dose-intensified weekly paclitaxel induces nail disorders. Ann oncol 9: 1139-41, 1998.
43. Flory SM, Solimando DA, Webster GF et al.: Onycholysis associated with weekly administration of paclitaxel. Ann Pharmacother 33(5): 584-86, 1999.
44. Belotti D, Vergani V, Drudis T et al.: The micrtotubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843-49, 1996.
45. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM and Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26 (Suppl 12): 60-70, 1999.
46. Gelmon K, Arnold A, Verma S et al.: Pharmacokinetics (PK) and safety of trastuzumab (Herceptin) when administered every three weeks to women with metastatic breast cancer. Proceedings of ASCO (20), 69a (abstract 271), 2001.
47. Baselga J, Castaneda-Soto N-J, Clemens M, Green M, Harvey V, Barton C and Morales S: Safety of Herceptin® monotherapy administered on a 3-weekly schedule: preliminary data from a phase II study. EBCC 2002.
48. Harris K, Washington CB, Lu J, Lieberman G, Mass B and Bruno R: A population pharmacokinetic (PK) model for herceptin® (H) and implications for clinical dosing. Proc Am Soc Clin Oncol 21: 2002.